Rani Therapeutics Holdings, Inc. (RANI) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in San Jose, CA, United States. The current CEO is Mir A. Imran.
RANI has IPO date of 2021-07-30, 105 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $62.71M.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
